Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.
Saved in:
| Title: | Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. |
|---|---|
| Authors: | Hayashi H; Department of Medical Oncology, Kindai University Faculty of Medicine, and Kindai Hospital Global Research Alliance Center (KHGRAC), Sakai, Osaka, Japan., Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Kim YJ; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea., Lee SH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Danchaivijitr P; Division of Medical Oncology, Department of Medicine, Siriraj Hospital Faculty of Medicine, Mahidol University Bangkok Noi Campus, Bangkok, Thailand., Alip A; Clinical Oncology Department, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Xiong H; Department of Medical Oncology, Huizhou Municipal Central Hospital of Guangdong Province, Huizhou, China., How SH; Department of Internal Medicine, Division of Respiratory Medicine, International Islamic University Malaysia, Pahang, Malaysia., Chang GC; School of Medicine and Institute of Medicine, Chung Shan Medical University and Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan., Yang JC; National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan., Yamanaka Y; Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan., Nahit Şendur MA; Department of Medical Oncology, Ankara Bilkent City Hospital and Ankara Yıldırım Beyazıt University, Ankara, Turkey., Prabhash K; Department of Medical Oncology, Division of Adult Solid Tumor Oncology, Tata Memorial Hospital, Mumbai, India., Azuma K; Kurume University School of Medicine, Kurume, Japan., Akawung A; Johnson & Johnson, Chestermere, AB, Canada., Fennema E; Johnson & Johnson, San Diego, CA, USA., Tang X; Johnson & Johnson, Shanghai, China., Shah S; Johnson & Johnson, Spring House, PA, USA., Sethi S; Johnson & Johnson, Spring House, PA, USA., Lu S; Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: shunlu@sjtu.edu.cn. |
| Source: | Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2026 Apr; Vol. 214, pp. 109305. Date of Electronic Publication: 2026 Feb 04. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
